GP IIb/IIIa inhibitors in coronary artery disease management: what the latest trials tell us
- PMID: 11765119
- DOI: 10.3949/ccjm.68.12.1017
GP IIb/IIIa inhibitors in coronary artery disease management: what the latest trials tell us
Abstract
Recent clinical trials have refined our understanding of how the glycoprotein (GP) IIb/IIIa inhibitors should best be used. These trials examined whether there are clinical differences between agents, whether empiric use of GP IIb/IIIa inhibitors in acute coronary syndromes is justified, and whether these drugs might allow for early invasive management in acute coronary syndromes.
Similar articles
-
Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.JAMA. 2000 Sep 27;284(12):1549-58. doi: 10.1001/jama.284.12.1549. JAMA. 2000. PMID: 11000650 Review.
-
[Therapy of acute coronary syndrome with glycoprotein IIb/IIIa antagonists].Med Clin (Barc). 2000 Oct 7;115(11):435-7. doi: 10.1016/s0025-7753(00)71582-x. Med Clin (Barc). 2000. PMID: 11093849 Spanish. No abstract available.
-
Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.Z Kardiol. 2003 Mar;92(3):213-8. doi: 10.1007/s00392-003-0895-6. Z Kardiol. 2003. PMID: 12658467 Review.
-
Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.Circulation. 2002 Sep 17;106(12):1470-6. doi: 10.1161/01.cir.0000029744.01096.1f. Circulation. 2002. PMID: 12234950 Clinical Trial.
-
Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.Cleve Clin J Med. 2000 Feb;67(2):131-40. doi: 10.3949/ccjm.67.2.131. Cleve Clin J Med. 2000. PMID: 10680279 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical